{"id":59321,"date":"2026-03-12T12:04:57","date_gmt":"2026-03-12T04:04:57","guid":{"rendered":"https:\/\/flcube.com\/?p=59321"},"modified":"2026-03-12T12:04:58","modified_gmt":"2026-03-12T04:04:58","slug":"boehringer-ingelheims-jascayd-nerandomilast-launches-in-shanghai-first-pde4b-inhibitor-for-idiopathic-pulmonary-fibrosis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59321","title":{"rendered":"Boehringer Ingelheim’s Jascayd (Nerandomilast) Launches in Shanghai \u2013 First PDE4B Inhibitor for Idiopathic Pulmonary Fibrosis"},"content":{"rendered":"\n

Boehringer Ingelheim<\/strong> announced the first prescription issuance<\/strong> for Jascayd (nerandomilast tablets)<\/strong> in Shanghai<\/strong>, marking the commercial launch<\/strong> of the world’s first approved selective PDE4B inhibitor<\/strong> for idiopathic pulmonary fibrosis (IPF)<\/strong> and progressive pulmonary fibrosis (PPF)<\/strong>. The drug, which received China marketing authorization in October 2025<\/strong>, offers multifaceted anti-fibrotic, vascular protective, and immunomodulatory effects<\/strong> with a favorable safety profile<\/strong> designed to address the high discontinuation rates<\/strong> associated with existing therapies.<\/p>\n\n\n\n

Commercial Launch Milestone<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Product<\/strong><\/td>Jascayd (nerandomilast tablets)<\/td><\/tr>
Generic Name<\/strong><\/td>Nerandomilast<\/td><\/tr>
Drug Class<\/strong><\/td>Selective phosphodiesterase 4B (PDE4B) inhibitor \u2013 first-in-class globally<\/strong><\/td><\/tr>
Indications<\/strong><\/td>Idiopathic pulmonary fibrosis (IPF); progressive pulmonary fibrosis (PPF)<\/td><\/tr>
Mechanism<\/strong><\/td>Anti-fibrotic activity + vascular protection + immunomodulation<\/td><\/tr>
Developer<\/strong><\/td>Boehringer Ingelheim<\/td><\/tr>
China Approval<\/strong><\/td>October 2025<\/td><\/tr>
First Prescription<\/strong><\/td>March 6, 2026 (Shanghai)<\/td><\/tr>
Key Differentiation<\/strong><\/td>Improved tolerability vs. existing IPF therapies (nintedanib, pirfenidone)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Profile & Unmet Need<\/h2>\n\n\n\n
Parameter<\/th>Jascayd (Nerandomilast)<\/th>Existing Therapies (Nintedanib\/Pirfenidone)<\/th>Clinical Advantage<\/th><\/tr><\/thead>
Efficacy<\/strong><\/td>Significantly slows lung function decline (FVC)<\/td>Modest FVC decline reduction<\/td>Comparable efficacy<\/td><\/tr>
Safety\/Tolerability<\/strong><\/td>Favorable profile<\/strong><\/td>High discontinuation rates due to GI toxicity (nintedanib) \/ photosensitivity (pirfenidone)<\/td>Reduced treatment discontinuation<\/strong><\/td><\/tr>
Mechanism<\/strong><\/td>Selective PDE4B inhibition (anti-fibrotic + immunomodulatory)<\/td>Multi-kinase inhibition (nintedanib) \/ unclear (pirfenidone)<\/td>Targeted mechanism; potentially better tolerability<\/td><\/tr>
Patient Compliance<\/strong><\/td>Expected improvement<\/td>~30-40% discontinuation within 12 months<\/td>Addresses critical unmet need<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Strategic Value<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
IPF\/PPF Burden<\/strong><\/td>China: 500,000+ IPF patients; rising diagnosis rates with improved HRCT access; median survival 3-5 years without treatment<\/td><\/tr>
Existing Therapy Limitations<\/strong><\/td>Nintedanib and pirfenidone slow decline but poorly tolerated; ~50% of patients discontinue or refuse initiation<\/td><\/tr>
Jascayd Positioning<\/strong><\/td>First-line option for treatment-na\u00efve patients; switch option for intolerant patients; potential for combination<\/td><\/tr>
Boehringer Portfolio<\/strong><\/td>Complements Ofev (nintedanib) with differentiated mechanism; addresses portfolio gap in tolerability-driven market<\/td><\/tr>
Global Expansion<\/strong><\/td>China-first approval strategy; U.S.\/EU filing anticipated 2026-2027 based on China data package<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Competitive Landscape<\/h2>\n\n\n\n
Product<\/th>Developer<\/th>Mechanism<\/th>China Status<\/th>Jascayd Differentiation<\/th><\/tr><\/thead>
Ofev (nintedanib)<\/strong><\/td>Boehringer Ingelheim<\/td>Multi-kinase inhibitor (VEGFR, FGFR, PDGFR)<\/td>Approved (IPF, PPF)<\/td>Same company; nerandomilast offers improved tolerability alternative<\/td><\/tr>
Esbriet (pirfenidone)<\/strong><\/td>Roche<\/td>Anti-fibrotic (mechanism unclear)<\/td>Approved (IPF)<\/td>Selective PDE4B mechanism vs. unclear MOA; better safety profile<\/td><\/tr>
Jascayd (nerandomilast)<\/strong><\/td>Boehringer Ingelheim<\/strong><\/td>Selective PDE4B inhibitor<\/strong><\/td>Launched (March 2026)<\/strong><\/td>First-in-class; tolerability advantage; multifaceted mechanism<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Launch Execution & Forward Outlook<\/h2>\n\n\n\n